NIKKEI 225
38,886.77 +269.67 (+0.70%) HANG SENG
18,834.61 -360.99 (-1.88%) CRUDE OIL
76.95 -0.62 (-0.80%) GOLD FUTURES
2,373.70 -19.20 (-0.80%) DOW
39,671.04 -201.95 (-0.51%) Bitcoin GBP
54,646.28 -586.19 (-1.06%)
AUTL Dec 2024 2.500 call
| Previous close | 1.8500 |
| Open | 1.0300 |
| Bid | 0.0000 |
| Ask | 2.1500 |
| Strike | 2.50 |
| Expiry date | 2024-12-20 |
| Day's range | 1.0300 - 1.8500 |
| Contract range | N/A |
| Volume | |
| Open interest | 11 |
- Thomson Reuters StreetEvents
Q1 2024 Autolus Therapeutics PLC Earnings Call
Q1 2024 Autolus Therapeutics PLC Earnings Call
GlobeNewswireAutolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
Longer follow up and subset analyses from the pivotal FELIX Phase 2 data to be presented in oral presentations at ASCO and EHATwo patients enrolled in Phase 1 Systemic Lupus Erythematosus (SLE) trial; study on track for initial data end of 2024Market Authorization Application (MAA) for obe-cel in r/r adult ALL accepted by European Medicines Agency (EMA)Conference call to be held today at 08:30 am EDT/13:30 pm BST: conference call participants should pre-register using the link at the bottom of t
- GlobeNewswire
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
LONDON, May 14, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the online publication of three abstracts submitted to the European Hematology Association (EHA) Congress, to be held June 13-16, 2024. Oral presentation: Title: obecabtagene autoleucel in adult relapsed/refractory B Cell acute lymphoblastic leukemia: Survival and potential impact of CAR-T cell persist
